Adenovirus delivery of encoded monoclonal antibody protects against different types of influenza virus infection

[1]  Dongming Zhou,et al.  Development of novel vaccine vectors: Chimpanzee adenoviral vectors , 2018, Human vaccines & immunotherapeutics.

[2]  P. S. Leventhal,et al.  Quadrivalent inactivated influenza vaccine (VaxigripTetra™) , 2018, Expert review of vaccines.

[3]  Honglin Chen,et al.  A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses , 2017, Science Translational Medicine.

[4]  R. Pebody,et al.  Live attenuated influenza vaccine (LAIV): recent effectiveness results from the USA and implications for LAIV programmes elsewhere , 2017, Archives of Disease in Childhood.

[5]  N. Sardesai,et al.  DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections , 2017, npj Vaccines.

[6]  A. Lanzavecchia,et al.  Tackling influenza with broadly neutralizing antibodies , 2017, Current Opinion in Virology.

[7]  Jun Cheng,et al.  Drug-Resistant and Genetic Evolutionary Analysis of Influenza Virus from Patients During the 2013 and 2014 Influenza Season in Beijing. , 2017, Microbial drug resistance.

[8]  Xiuli Wu,et al.  Progress of small molecular inhibitors in the development of anti-influenza virus agents , 2017, Theranostics.

[9]  R. Desrosiers,et al.  Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies , 2016, Molecular therapy. Methods & clinical development.

[10]  P. Collins,et al.  Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes , 2016, Cell.

[11]  R. Weiss,et al.  Development of broad‐spectrum human monoclonal antibodies for rabies post‐exposure prophylaxis , 2016, EMBO molecular medicine.

[12]  Andrew M Wollacott,et al.  Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks , 2016, EBioMedicine.

[13]  D. Barouch,et al.  Broadly Neutralizing Antibodies for HIV Eradication , 2016, Current HIV/AIDS Reports.

[14]  E. Burtseva,et al.  Virus susceptibility and clinical effectiveness of anti-influenza drugs during the 2010-2011 influenza season in Russia. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[15]  H. Ertl,et al.  Rapid, Efficient, and Modular Generation of Adenoviral Vectors via Isothermal Assembly , 2016, Current protocols in molecular biology.

[16]  H. Ertl,et al.  Repeated Low-Dose Influenza Virus Infection Causes Severe Disease in Mice: a Model for Vaccine Evaluation , 2015, Journal of Virology.

[17]  K. Swiderek,et al.  Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. , 2015, The Journal of infectious diseases.

[18]  N. Cox,et al.  H7N9: preparing for the unexpected in influenza. , 2015, Annual review of medicine.

[19]  S. Gupta.  Rabies vaccine , 2015, Reactions weekly.

[20]  James M. Wilson,et al.  Adeno-Associated Virus 9-Mediated Airway Expression of Antibody Protects Old and Immunodeficient Mice against Influenza Virus , 2014, Clinical and Vaccine Immunology.

[21]  Florian Krammer,et al.  Influenza virus hemagglutinin stalk-based antibodies and vaccines. , 2013, Current opinion in virology.

[22]  B. Jia,et al.  Seroprevalence of neutralizing antibodies to human adenoviruses type‐5 and type‐26 and chimpanzee adenovirus type‐68 in healthy Chinese adults , 2013, Journal of medical virology.

[23]  G. Wong,et al.  Intranasal Antibody Gene Transfer in Mice and Ferrets Elicits Broad Protection Against Pandemic Influenza , 2013, Science Translational Medicine.

[24]  N. S. Laursen,et al.  Highly Conserved Protective Epitopes on Influenza B Viruses , 2012, Science.

[25]  D. Burton,et al.  Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses , 2012, Science.

[26]  I. Wilson,et al.  Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. , 2012, Current opinion in virology.

[27]  Kousuke Saito,et al.  Clinical effectiveness of neuraminidase inhibitors—oseltamivir, zanamivir, laninamivir, and peramivir—for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010–2011 influenza season in Japan , 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[28]  Martin H. Koldijk,et al.  A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses , 2011, Science.

[29]  Z. Xiang,et al.  A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  M. Betts,et al.  Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens , 2009, The Journal of Immunology.

[31]  J. Taubenberger,et al.  The pathology of influenza virus infections. , 2008, Annual review of pathology.

[32]  P. Mahadevan,et al.  An overview , 2007, Journal of Biosciences.

[33]  Hildegund C.J. Ertl,et al.  Adenoviruses as vaccine vectors , 2004, Molecular Therapy.

[34]  J. Douglas.  Adenovirus-mediated gene delivery: an overview. , 2004, Methods in molecular biology.

[35]  S. Kochanek,et al.  A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. , 2003, Human gene therapy.

[36]  P. Rakoczy,et al.  Adenovirus and adeno-associated virus vectors. , 2002, DNA and cell biology.

[37]  Z. Xiang,et al.  Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. , 2002, The Journal of general virology.

[38]  Y. Isegawa,et al.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains , 1993, Journal of virology.

[39]  S. Chutivongse,et al.  Adverse effects of equine rabies immune gobulin. , 1989, Vaccine.

[40]  Rabies Vaccine Failures , 1988, The Lancet.

[41]  J. Skehel,et al.  The molecular basis of the specific anti‐influenza action of amantadine. , 1985, The EMBO journal.

[42]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .